InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
linwood42 Free
07/31/14 7:30 PM
profile icon
Maudie Free
06/21/14 8:45 AM
profile icon
Peggy Free
06/17/14 9:36 AM
profile icon
linwood42 Free
03/06/14 10:47 PM
profile icon
tbiggs85 Free
03/02/14 1:34 PM
profile icon
Sentrex1969 Free
02/07/14 11:15 AM
profile icon
linwood42 Free
01/16/14 11:43 PM
profile icon
Thinknot Free
01/16/14 2:11 PM
profile icon
Sentrex1969 Free
11/25/13 2:32 PM
profile icon
SELL ME Free
11/04/13 12:59 PM
profile icon
linwood42 Free
10/11/13 12:59 AM
profile icon
kweather Free
10/10/13 5:46 PM
profile icon
SELL ME Free
09/26/13 10:22 PM
profile icon
SELL ME Free
09/09/13 8:37 PM
profile icon
Penny Roger$ Free
08/28/13 8:10 PM
profile icon
KeaneO Free
08/25/13 8:36 PM
profile icon
SELL ME Free
08/21/13 12:38 AM
profile icon
linwood42 Free
08/20/13 1:44 PM
profile icon
KeaneO Free
08/18/13 10:25 PM
profile icon
SELL ME Free
08/18/13 1:44 AM
profile icon
linwood42 Free
08/16/13 8:52 PM
profile icon
KeaneO Free
08/16/13 1:08 PM
profile icon
Sentrex1969 Free
06/26/13 6:59 AM
profile icon
SELL ME Free
06/18/13 10:34 PM
profile icon
la7792 Free
06/17/13 9:56 AM
profile icon
zorro77 Free
06/08/13 3:33 PM
profile icon
Maudie Free
06/03/13 12:58 PM
profile icon
linwood42 Free
06/02/13 11:59 PM
profile icon
janaiy1 Free
06/01/13 12:55 PM
profile icon
janaiy1 Free
06/01/13 11:45 AM
profile icon
Expurience Terminated
05/28/13 10:26 AM
profile icon
zailo2009 Free
04/24/13 10:28 PM
profile icon
guessrightlol Free
04/24/13 3:09 PM
profile icon
SELL ME Free
04/24/13 12:05 AM
profile icon
Roy London Terminated
03/31/13 12:18 PM
profile icon
All in 4 Me Terminated
03/29/13 9:51 AM
profile icon
All in 4 Me Terminated
03/29/13 9:51 AM
profile icon
Maudie Free
03/29/13 8:24 AM
profile icon
linwood42 Free
03/28/13 4:17 PM
profile icon
SELL ME Free
03/18/13 4:33 PM
profile icon
Roy London Terminated
03/16/13 1:16 PM
profile icon
All in 4 Me Terminated
03/06/13 4:41 PM
profile icon
Penny Roger$ Free
03/06/13 12:34 AM

Kedem Pharmaceuticals, Inc.(fka KDMP) RSS Feed

Followers
47
Posters
278
Posts (Today)
0
Posts (Total)
6405
Created
10/09/09
Type
Free
Moderators

 

http://kedempharmaceuticals.com




  •  
  • Products
  •  
  •  
  • Our Technology
  • Featured Drug: Nico-Z

    Featured Drug: Nico-Z

  • Featured Drug: T-Slim

    Featured Drug: T-Slim

  • Better Technology

    Better Technology

 

MEDICAL TECHNOLOGIES FOR YOUR HEALTH

Consuming just under 10 percent of gross domestic product of most developed nations, health care can form an enormous part of a country's economy. In 2003, health care costs paid to hospitals, physicians, nursing homes, diagnostic laboratories, pharmacies, medical device manufacturers and other components of the health care system, consumed 16.3 percent of the GDP of the United States, the largest of any country in the world. For the United States, the health care share of gross domestic product (GDP) is expected to hold steady in 2006 before resuming its historical upward trend, reaching 19.5 percent of GDP by 2016. In 2001, for the OECD countries the average was 8.4 percent with the United States (13.9%), Switzerland (10.9%), and Germany (10.7%) being the top three.

As obesity is one of the leading preventable causes of death worldwide and with rates of adult and childhood obesity increasing, authorities view it as one of the most serious public health problem of the 21st century. Obesity is often stigmatized in the modern Western world. However, it has been perceived as a symbol of wealth and fertility at other times in history and still is in many parts of Africa.

The World Health Organization (WHO ) predicts that overweight and obesity may soon replace more traditional public health concerns such as undernutrition and infectious diseases as the most significant cause of poor health.Obesity is a public health and policy problem because of its prevalence, costs, and health effects. Public health efforts seek to understand and correct the environmental factors responsible for the increasing prevalence of obesity in the population. Solutions look at changing the factors that cause excess calorie consumption and inhibit physical activity. Efforts include federally reimbursed meal programs in schools, limiting direct junk food marketing to children, and decreasing access to sweetened beverages in schools.

 

"Major pharmaceutical companie are facing a steep revenue decline because of looming patent expirations and lack of innovation for new drugs. Specialty pharmas and biotech companies are becoming highly desirable due to their pipeline of new drugs and solid innovations. 

I believe a large number of young companies such as ours are to be the target of acquisition by these large multinational pharmaceutical companies. This shall reward our stockholders handsomely when the acquisition are made."


Hassan Salari, Ph.D. 
Chairman & CEO Dr.

 

 

 

 

 
       

Products

Our product portfolio includes orodispersable version of both generic and brand products. Our products, follow a 505 (b)2 regulatory pathway as designed by FDA. The therapeutic areas covered by our portfolio include sexual enhancement, psychotics, cardiovascular, pulmonary, pain and analgesics.

The most advanced product in our portfolio includes a sublingual formulation of sildenafil citrate. Sildenafil is registered for erectile dysfunction under the trade name of ViagraTM.

The second most advanced product in our generics pipeline is Propranolol, a generic version of the marketed drug. This product is currently the subject of a reformulation for cardiovascular and hypertension.

Following table demonstrates our current product pipeline:

pipeline


 
 

Our Technology

Our sublingual and orodispersable technology applies ingredients approved by FDA as drug excipients. The formulation create drug tablets that have disintegration time of less than 20 second and rapid dissolution time. Our technologies are based upon the drug active being imbedded in, and an integral part of, a homogeneous (uniform) core consisting of one or more excipients that affect the release rates of drugs. Our technology allows for the efficient design of drugs through the precise manipulation of a number of key variables. This allows us to respond to varying drug attributes and patient requirements, producing a desired taste and cost effective manner.

Board Info
Posts Today
0
Posts (Total)
6405
Posters
278
Moderators
New Post